Trial Profile
Oral Anticoagulant Bleeding Rate and Discontinuation and Adherence Patterns in Non-Valvular Atrial Fibrillation (NVAF) Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2016
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Warfarin
- Indications Embolism and thrombosis
- Focus Adverse reactions
- 27 May 2015 New trial record